1
Barun Okram, Pingda Ren, Nathanael S Gray: Compounds and compositions as protein kinase inhibitors. IRM, The Scripps Research Institute, Scott W Reid, Genomics Institute of the Novartis Research Foundation, September 15, 2009: US07589101 (8 worldwide citation)

The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve ...


2
Nathanael Gray, Jianming Zhang, Barun Okram, Xianming Deng, Jae Won Chang: Small molecule myristate inhibitors of BCR-ABL and methods of use. Dana Farber Cancer Institute, The Scripps Research Institute, Brinks Gilson & Lione, December 30, 2014: US08921336

The present invention provides novel heteroaryl compounds of formula (I) having a pyrimidine-containing core that is linked to a 4-trifluoromethoxyphenyl group via an amine linker. Such compounds are useful for the treatment of cancers.


3
Barun Okram, Tetsuo Uno, Qiang Ding, Yahua Liu, Yunho Jin, Qihui Jin, Xu Wu, Jianwei Che, S Frank Yan, Xueshi Hao: Compounds and compositions as kinase inhibitors. IRM, Daniel E Raymond, Genomics Institute of the Novartis Research Foundation, October 1, 2013: US08546370

The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, ...


4
Jianwei Che, Qiang Ding, Xiaohui He, Hong Liu, Yahua Liu, Pierre Yves Michellys, Barun Okram, Xu Wu, Kunyong Yang, Xuefeng Zhu: Compounds and compositions as Syk kinase inhibitors. Daniel E Raymond, Genomics Institute of the Novartis Research Foundation, May 13, 2014: US08722692

Provided herein are a novel class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.


5
Pingda Ren, Baogen Wu, Guobao Zhang, Yongping Xie, Barun Okram, Victor Nikulin, Xia Wang, Ha Soon Choi: Compounds and compositions as protein kinase inhbitors. IRM, Emily Tongco Wu, Genomics Institute of the Novartis Research Foundation, December 7, 2010: US07846923

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal act ...


6
Barun Okram, Pingda Ren, Nathanael S Gray: Compounds and Compositions as Protein Kinase Inhibitors. Irm, The Scripps Research Institute, Genomics Institute Of The, Novartis Research Foundation, November 20, 2008: US20080287432-A1

The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve ...


7
Barun Okram, Pingda Ren, Nathanael S Gray: Compounds and Compositions as Protein Kinase Inhibitors. Genomics Institute Of The, Novartis Research Foundation, December 4, 2008: US20080300267-A1

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal act ...


8
Jianwei CHE, Bei Chen, Qiang Ding, Xueshi Hao, Xiaohui He, Songchun Jiang, Qihui Jin, Yunho Jin, Hong Liu, Yahua Liu, Barun Okram, Tetsuo Uno, Xu Wu, Kunyong Yang, Xuefeng Zhu: Compounds and compositions as syk kinase inhibitors. Irm, March 3, 2011: US20110053897-A1

Provided herein area novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.


9
Barun Okram, Tetsuo Uno, Qiang Ding, Yahua Liu, Yunho Jin, Qihui Jin, Xu Wu, Jianwei Che, S Frank Yan, Xueshi Hao: Compounds and compositions as kinase inhibitors. Irm, Genomics Institute Of The, Novartis Research Foundation, January 6, 2011: US20110003798-A1

The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat o prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT*, c ...


10
Pingda Ren, Baogen Wu, Guobao Zhang, Yongping Xie, Barun Okram, Victor Nikulin, Xia Wang, Ha Soon Choi: Compounds and compositions as protein kinase inhbitors. Irm, Genomics Institute Of The, Novartis Research Foundation, February 25, 2010: US20100048552-A1

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal act ...